Compare IDEXX Laboratories, Inc. (IDXX) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs ING Groep NV — how do they compare? IDEXX Laboratories, Inc. trades at $571.7 (market cap $46.22B), while ING Groep NV trades at $35.61 (market cap $101.22B). The key difference: ING Groep NV is far larger — about 2.2× IDEXX Laboratories, Inc.'s market cap, and ING Groep NV pays a 3.73% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | ING | |
|---|---|---|
Market Cap | $46.22B | $101.22B |
Sector | Health | Financials |
52-Week High | $766.68 | $35.92 |
52-Week Low | $526.44 | $23.66 |
Enterprise Value | $47.12B | — |
Dividend Yield | — | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
ING Groep (ING) trades at $35.61, up 1.05% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $0.79 exceeding expectations. Revenue growth remains stable at $22.9B for 2025, supported by a robust 28.34% net income margin and 13.49% ROE. Recent guidance upgrades and strategic acquisitions in wealth management signal management confidence in future growth prospects.
The outlook remains positive with 62.5% analyst buy ratings and technical indicators supporting further upside. Key risks include negative operating cash flows and European banking sector volatility. The stock's attractive 13.24 P/E ratio and dividend yield provide value appeal, though investors should monitor cash flow trends and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
